Summary of case reports and series of bendamustine-induced immune hemolytic anemia
| Reference/year . | n . | Age, y/sex . | Hematologic diagnosis (n) . | No. of bendamustine cycles prior to hemolysis . | Prior nonbendamustine purine analog exposure (n) . | Low platelets (nadir platelet count) . | DAT status . | Treatment . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| Cuneo et al7 /2018 | 2 | NR | CLL (2) | NR | Fludarabine Chlorambucil | NR | NR | NR | NR |
| Fischer et al8 /2011 | 2 | NR | CLL (2) | NR | Fludarabine Fludarabine | NR | NR | NR | NR |
| Glance et al9 /2009 | 1 | 64/female | FL (1) | 4 | No | Yes (16) | Negative | P 1 mg/kg | Recovered |
| Goldschmidt et al10 /2013 | 5 | 69/male63/female66/female59/male54/male | CLL (5) | 1 2 6 1 1 | Fludarabine Fludarabine Chlorambucil Fludarabine Fludarabine | NR | IgG+ C3+ Negative IgG+ Negative | P, R P, R, C P M, I, R, C P, R | Recovered (4/5) Death (1/5) |
| Haddad et al11 /2014 | 1 | 70/female | CLL (1) | 3 | Fludarabine | NR | IgG+, C3+ | P 1 mg/kg | Recovered |
| Hodskins et al12 /2014 | 1 | 62/male | CLL (1) | 1 | No | NR | Positive | P | Recovered |
| Knauf et al13 /2009 | 2 | NR | CLL (2) | NR | No (2) | NR | NR | NR | NR |
| Laurenti et al14 /2016 | 6 | 58/female62/female68/male64/female63/female68/male | CLL (6) | 6 4 2 3 4 1 | No No Fludarabine Fludarabine Fludarabine Chlorambucil | NR | Positive IgG+ Positive Negative Negative IgG+ | P P P, R, C, V R P P | Recovered (6/6) |
| Nyatanga et al15 /2015 | 5 | 63 (median)56-69 (range) | CLL (5) | NR | Fludarabine (3) | NR | NR | P (3) P, R (1) P, R, C (1) | Recovered (5/5) |
| Spacek et al16 /2019 | 1 | NR | CLL (1) | NR | NR | NR | NR | NR | NR |
| Reference/year . | n . | Age, y/sex . | Hematologic diagnosis (n) . | No. of bendamustine cycles prior to hemolysis . | Prior nonbendamustine purine analog exposure (n) . | Low platelets (nadir platelet count) . | DAT status . | Treatment . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| Cuneo et al7 /2018 | 2 | NR | CLL (2) | NR | Fludarabine Chlorambucil | NR | NR | NR | NR |
| Fischer et al8 /2011 | 2 | NR | CLL (2) | NR | Fludarabine Fludarabine | NR | NR | NR | NR |
| Glance et al9 /2009 | 1 | 64/female | FL (1) | 4 | No | Yes (16) | Negative | P 1 mg/kg | Recovered |
| Goldschmidt et al10 /2013 | 5 | 69/male63/female66/female59/male54/male | CLL (5) | 1 2 6 1 1 | Fludarabine Fludarabine Chlorambucil Fludarabine Fludarabine | NR | IgG+ C3+ Negative IgG+ Negative | P, R P, R, C P M, I, R, C P, R | Recovered (4/5) Death (1/5) |
| Haddad et al11 /2014 | 1 | 70/female | CLL (1) | 3 | Fludarabine | NR | IgG+, C3+ | P 1 mg/kg | Recovered |
| Hodskins et al12 /2014 | 1 | 62/male | CLL (1) | 1 | No | NR | Positive | P | Recovered |
| Knauf et al13 /2009 | 2 | NR | CLL (2) | NR | No (2) | NR | NR | NR | NR |
| Laurenti et al14 /2016 | 6 | 58/female62/female68/male64/female63/female68/male | CLL (6) | 6 4 2 3 4 1 | No No Fludarabine Fludarabine Fludarabine Chlorambucil | NR | Positive IgG+ Positive Negative Negative IgG+ | P P P, R, C, V R P P | Recovered (6/6) |
| Nyatanga et al15 /2015 | 5 | 63 (median)56-69 (range) | CLL (5) | NR | Fludarabine (3) | NR | NR | P (3) P, R (1) P, R, C (1) | Recovered (5/5) |
| Spacek et al16 /2019 | 1 | NR | CLL (1) | NR | NR | NR | NR | NR | NR |
C, cyclophosphamide; FL, follicular lymphoma; I, IV immunoglobulin; M, methylprednisolone; NR, not reported; P, prednisone; R, rituximab; V, vincristine.